Fazarabine: a report of response in a patient with multiply relapsed embryonal cell carcinoma

Am J Clin Oncol. 1993 Feb;16(1):34-7.

Abstract

This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy. The antimetabolic Ara-AC is worthy of further study in patients with germ-cell tumors. It would appear that the antimetabolite Ara-AC may have significant activity in patients with germ-cell tumors.

Publication types

  • Case Reports
  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Azacitidine / therapeutic use*
  • Humans
  • Male
  • Neoplasms, Germ Cell and Embryonal / drug therapy*
  • Neoplasms, Germ Cell and Embryonal / secondary*

Substances

  • Antineoplastic Agents
  • fazarabine
  • Azacitidine